Cargando…

A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy

The chemotherapeutics sorafenib and regorafenib inhibit shedding of MHC class I-related chain A (MICA) from hepatocellular carcinoma (HCC) cells by suppressing a disintegrin and metalloprotease 9 (ADAM9). MICA is a ligand for natural killer (NK) group 2 member D (NKG2D) and is expressed on tumor cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Sooyeon, Park, YoungJoon, Lee, Hyun-Jung, Lee, Jooho, Lee, Soo-Hyeon, Baek, Young-Seok, Chun, Su-Kyung, Lee, Seung-Min, Kim, Mina, Chon, Young-Eun, Ha, Yeonjung, Cho, Yuri, Kim, Gi Jin, Hwang, Seong-Gyu, Kwack, KyuBum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140088/ https://www.ncbi.nlm.nih.gov/pubmed/32245188 http://dx.doi.org/10.3390/cancers12030745

Ejemplares similares

The disintegrin-metalloproteinases ADAM10 and ADAM17 are upregulated in cutaneous squamous cell carcinomas
por: Oh, S.-T., et al.
Publicado: (2016)

MicroRNA-425 promotes the development of lung adenocarcinoma via targeting A disintegrin and metalloproteinases 9 (ADAM9)
por: Liu, Ruibao, et al.
Publicado: (2018)

Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma
por: Oh, Sooyeon, et al.
Publicado: (2020)

Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy
por: Moriwaki, Michika, et al.
Publicado: (2022)

A Disintegrin and Metalloproteinase 9 Domain (ADAM9) Is a Major Susceptibility Factor in the Early Stages of Encephalomyocarditis Virus Infection
por: Bazzone, Lindsey E., et al.
Publicado: (2019)

Molecular switch in human diseases-disintegrin and metalloproteinases, ADAM17
por: Yang, Guang, et al.
Publicado: (2021)

Relationship Between Proteinase with a Disintegrin and a Metalloproteinase Domain-9 (ADAM9), Inflammation, Airway Remodeling, and Emphysema in COPD Patients
por: Cui, Liwei, et al.
Publicado: (2020)

Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma
por: Honda, Hiroki, et al.
Publicado: (2017)

Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
por: Ha, Yeonjung, et al.
Publicado: (2020)

Expression of Tissue Inhibitors of Metalloproteinases (TIMPs) in Hepatocellular Carcinoma
por: Joo, Young-Eun, et al.
Publicado: (2000)

Deficiency of the Metalloproteinase-Disintegrin ADAM8 Is Associated with Thymic Hyper-Cellularity
por: Gossens, Klaus, et al.
Publicado: (2010)

A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma
por: Kanzaki, Hiroyuki, et al.
Publicado: (2016)

Vitamin D and Exercise Are Major Determinants of Natural Killer Cell Activity, Which Is Age- and Gender-Specific
por: Oh, Sooyeon, et al.
Publicado: (2021)

Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids
por: Matthews, Alexandra L., et al.
Publicado: (2017)

Phenotypic Diversity of Breast Cancer-Related Mutations in Metalloproteinase-Disintegrin ADAM12
por: Qi, Yue, et al.
Publicado: (2014)

Overexpression of ADAM9 decreases radiosensitivity of hepatocellular carcinoma cell by activating autophagy
por: Zhu, Lijin, et al.
Publicado: (2021)

Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10
por: Goto, Kaku, et al.
Publicado: (2018)

Inhibition of hepatocellular carcinoma cell proliferation, migration, and invasion by a disintegrin and metalloproteinase-17 inhibitor TNF484
por: Xia, Changhong, et al.
Publicado: (2019)

Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B
por: Lim, Jihye, et al.
Publicado: (2021)

A Disintegrin and Metalloproteinase (ADAM) Family—Novel Biomarkers of Selected Gastrointestinal (GI) Malignancies?
por: Łukaszewicz-Zając, Marta, et al.
Publicado: (2022)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
por: Chon, Young Eun, et al.
Publicado: (2022)

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lee, Yun Bin, et al.
Publicado: (2019)

Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function
por: Ha, Yeonjung, et al.
Publicado: (2018)

A Disintegrin and Metalloproteinase (ADAM) Family: Their Significance in Malignant Tumors of the Central Nervous System (CNS)
por: Łukaszewicz-Zając, Marta, et al.
Publicado: (2021)

A Disintegrin and Metalloproteinase Protein 8 (ADAM 8) in Autism Spectrum Disorder: Links to Neuroinflammation
por: Al-Ayadhi, Laila, et al.
Publicado: (2023)

Molecular characterization and expression of a disintegrin and metalloproteinase with thrombospondin motifs 8 in chicken
por: Lee, Ra Ham, et al.
Publicado: (2018)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
por: Kim, Beom Kyung, et al.
Publicado: (2022)

Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors
por: Oh, Sooyeon, et al.
Publicado: (2019)

Downregulation of LOC441461 Promotes Cell Growth and Motility in Human Gastric Cancer
por: Lee, Sang-soo, et al.
Publicado: (2022)

The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor
por: Atfi, Azeddine, et al.
Publicado: (2007)

A Disintegrin and Metalloproteinase10 (ADAM10) Regulates NOTCH Signaling during Early Retinal Development
por: Toonen, Joseph A., et al.
Publicado: (2016)

A Novel Pro-Inflammatory Mechanosensing Pathway Orchestrated by the Disintegrin Metalloproteinase ADAM15 in Synovial Fibroblasts
por: Janczi, Tomasz, et al.
Publicado: (2021)

Potential role of a disintegrin and metalloproteinase-17 (ADAM17) in age-associated ventricular remodeling of rats
por: Liu, Hainiang, et al.
Publicado: (2019)

A Disintegrin and Metalloproteinase 10 (ADAM10) Is Essential for Oligodendrocyte Precursor Development and Myelination in the Mouse Brain
por: Guo, Dazhi, et al.
Publicado: (2022)

A Case of Hepatocellular Carcinoma Within Hepatocellular Adenoma in a Non-Cirrhotic Male
por: Kim, Dong Hwan, et al.
Publicado: (2009)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma
por: Hyeon, Jiyeon, et al.
Publicado: (2013)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Single‐nucleotide polymorphisms in the coding region of a disintegrin and metalloproteinase with thrombospondin motifs 4 and hepatocellular carcinoma: A retrospective case‐control study
por: Wang, Xing‐Zhizi, et al.
Publicado: (2019)

The Expression of Estrogen Receptors in Hepatocellular Carcinoma in Korean Patients
por: Wang, Ai Guo, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_i7mb6srpiqdcg58i2je2f3hvra